Since there was higher prevalence of metastatic cancers in cachectic patients (P = 0.013), we reanalyzed the data using two-way ANOVA and found both cachexia (P = 0.012) and metastatic status (P < 0.001) to be independently associated with serum resistin. The gene discussed is RETN; the disease is Cachexia.